Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous parecoxib for prevention of post-ERCP pancreatitis
TCTR20221020002Phase 4Unknown
- Sponsor
- MedStar National Rehabilitation Hospital Institutional Review Board
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of parecoxib in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP), sponsored by MedStar National Rehabilitation Hospital Institutional Review Board. Status: unknown.
02
Drugs
parecoxib
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on TCTR20221020002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20221020002.